Overview

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Status:
Recruiting
Trial end date:
2023-07-18
Target enrollment:
Participant gender:
Summary
Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Candesartan